67th WHA Side Event on Innovation and Access for Middle-Income Countries, Wednesday 21 May 2014

This Wednesday 21 May 2014, Knowledge Ecology International (KEI), Civil Society Coalition, Medecins Sans Frontieres (MSF), Oxfam, Health Action International (HAI) and Treatment Action Group (TAG) will host a side event at the WHA on, “Innovation and Access to Medicines and Vaccines: Emerging Challenges and Opportunities for Middle-Income Countries.”

Continue Reading

Colombian Submission to the WHO IGWG negotiation favors drug company positions on IP

By resolution WHA 59.24, the WHO’s Intergovernmental Working Group on Public Health, Innovation, and Intellectual Property (IGWG) has the goal of producing a Global Strategy and Plan of Action that will implement the CIPIH report recommendations and “secure an enhanced and sustainable basis for needs-driven, essential health research and development relevant to diseases that disproportionately affect developing countries, proposing cle Continue Reading

KEI Letter to Thailand Prime Minister and Health Minister, regarding compulsory licensing decisions

His Excellency Mr. Samak Sundaravej Prime Minister Government House Nakornpratom Rd. Dusit, Bangkok Thailand 10300 His Excellency Mr. Chaiya Sasomsap Minister of Public Health Tiwanont Rd. Talad Kwan District Nontaburi Province 11000 Thailand March 4, 2008 Re: Thailand Compulsory Licenses… Continue Reading

Thailand’s Compulsory Licensing Controversy

Between November 2006 and January 2007, Thailand issued compulsory licenses for two AIDS drugs (efavirnz and the combination of lopinavir+ritonavir) and one antihypertension drug (clopidegrel).  The pharmaceutical industry has vehemently objected to these compulsory licenses, and has sought the US… Continue Reading

Notes from March 16th 2007 U.S. Capitol Briefing on Thailand’s Compulsory Licenses

On Friday, March 16, KEI organized a briefing in the U.S. Capitol on Thailand’s recent compulsory licenses on three drugs; two for HIV/AIDS (Merck’s efavirenz (Stocrin) and Abbott’s lopinavir + ritonavir (Kaletra)) and one for heart disease (Sanofi’s clopidogrel (Plavix)). … Continue Reading

European Commission Response to CPTech Letter Regarding EU Opt-out of WTO Compulsory Licensing Mechanism

Original page: http://www.cptech.org/ip/wto/p6/eu12052005.pdf Letter from CPTech referenced available here: https://www.keionline.org/32641 MARKOS KYPRIANOU                                            PETER MANDELSON Member of the European Commission … Continue Reading

Christine LAGARDE asked to change EU “opt-out” of 30 August 2003 decision regarding imports of generic medicines manufactured under a compulsory license

Original page: http://www.cptech.org/ip/health/tamiflu/christinelagarde.html Christine LAGARDE asked to change EU “opt-out” of 30 August 2003 decision regarding imports of generic medicines manufactured under a compulsory license To: Christine LAGARDE, Ministre déléguée au Commerce extérieur, France From: Manon Ress and James Love,… Continue Reading

CPTech Letter to EC Director General of Trade Peter Mandelson

Original page: http://www.cptech.org/ip/health/tamiflu/cptech-mandelson10192005.html CPTech Letter to EC Director General of Trade Peter Mandelson 19th October 2005 Commissioner Mandelson EUROPEAN COMMISSION DG Trade 200 rue de la Loi B-1049 BRUSSELS Dear Commissioner Mandelson TRIPS Agreement and Avian Influenza We ask the… Continue Reading

CPTech Letter to USTR Portman Regarding US Position on WTO Opt-Out of Compulsory Licensing Mechanism

Original page: http://www.cptech.org/ip/birdflu/ustr-birdflu.html 14 October 2005 Honorable Rob Portman United States Trade Representative 600 17th Street, N.W. Washington, DC 20508 Dear Ambassador Portman: We are writing to ask that the United States government address a mistake in trade policy that… Continue Reading